---
id: 145
title: Haemophilus influenzae Infections
category: organisms
subcategory: gram_negative_rods
tags: [H-influenzae, Hib, meningitis, epiglottitis, vaccine, ampicillin-resistance]
difficulty: medium
---

## Question

How has *H. influenzae* disease changed post-vaccination? Use the **"Hib Vaccine = Eliminated Type b, Non-Typeable Now Dominates"** framework.

## Answer

### ***Haemophilus influenzae* Overview:**

**Types:**
- **Encapsulated (Types a-f):** Type b (Hib) was most common pre-vaccine
- **Non-typeable (NTHi):** No capsule, now most common cause of disease post-Hib vaccine

### **Clinical Syndromes:**

**Pre-Hib Vaccine Era (Type b):**
- **Meningitis** (most common, children <5 years)
- **Epiglottitis** (life-threatening airway emergency)
- **Bacteremia/sepsis**
- **Cellulitis** (facial, periorbital)
- **Septic arthritis**, **osteomyelitis**
- **Pneumonia**

**Post-Hib Vaccine Era (Non-Typeable):**
- **Otitis media** (children) - most common
- **Sinusitis**
- **COPD exacerbations** (adults)
- **Pneumonia** (adults, especially COPD)
- **Invasive disease rare** (mostly in unvaccinated or immunocompromised)

### **Treatment:**

**Empiric (Before Susceptibilities):**
- **Ceftriaxone 2g IV daily** OR **cefotaxime 2g IV q4-6h**
- **Reason:** 30-40% ampicillin-resistant (β-lactamase production)

**Definitive (Based on Susceptibilities):**

| Susceptibility | Treatment | Notes |
|----------------|-----------|-------|
| **Ampicillin-susceptible** | **Ampicillin 2g IV q4h** | Only 60-70% susceptible |
| **Ampicillin-resistant** | **Ceftriaxone 2g IV daily** OR **cefotaxime** | β-lactamase production |
| **β-lactam allergy** | **Fluoroquinolone** (levofloxacin, moxifloxacin) OR **azithromycin** | |

**Duration:**
- **Meningitis:** 7-10 days
- **Epiglottitis:** 7-10 days
- **Bacteremia:** 10-14 days
- **Pneumonia:** 7-14 days

### **Epiglottitis (Medical Emergency):**

**Presentation:**
- **4 D's:** **Dysphagia**, **Drooling**, **Distressed**, **Dysphonia** (muffled voice)
- **Tripod position** (leaning forward, mouth open)
- **Stridor**, respiratory distress
- **High fever**, toxic appearance
- **Rapid progression** to airway obstruction

**Diagnosis:**
- **Lateral neck X-ray:** **"Thumb sign"** (swollen epiglottis)
- **DO NOT examine throat** (can precipitate complete obstruction)

**Management:**
- **Secure airway FIRST** (intubation in OR with ENT/anesthesia backup)
- **Ceftriaxone 2g IV daily** × 7-10 days
- **Blood cultures** before antibiotics

### **Hib Vaccine:**

**Schedule:**
- **2, 4, 6, 12-15 months** (PRP-T or PRP-OMP)
- **Dramatically reduced** invasive Hib disease (>99% reduction)

**Post-Exposure Prophylaxis:**
- **Rifampin 20 mg/kg (max 600mg) daily × 4 days** for:
  - Household contacts if unvaccinated or incompletely vaccinated child <4 years in home
  - Daycare contacts if ≥2 cases in 60 days
- **Index case:** Give rifampin before discharge (eradicate nasopharyngeal carriage)

## Key Points

### **Ampicillin Resistance:**
- **Mechanism:** β-lactamase production (TEM-1 most common)
- **Prevalence:** 30-40% in US
- **Always use ceftriaxone/cefotaxime empirically** for serious infections

### **Non-Typeable H. influenzae (NTHi):**
- **Most common cause** of *H. influenzae* disease post-Hib vaccine
- **Mucosal infections:** Otitis media, sinusitis, COPD exacerbations
- **Less invasive** than type b (no capsule)
- **Biofilm formation** (difficult to eradicate in chronic infections)

### **COPD Exacerbations:**
- **NTHi** = common bacterial cause (along with *S. pneumoniae*, *M. catarrhalis*)
- **Treatment:** Amoxicillin-clavulanate, doxycycline, or fluoroquinolone

### **Culture Requirements:**
- **Chocolate agar** (requires factors V [NAD] and X [hemin])
- **Gram stain:** Small Gram-negative coccobacilli (pleomorphic)

### **Clinical Pearls:**
- **Hib vaccine eliminated** invasive type b disease (>99% reduction)
- **Non-typeable now dominant:** Otitis media, sinusitis, COPD exacerbations
- **Epiglottitis:** 4 D's (dysphagia, drooling, distressed, dysphonia) → secure airway FIRST
- **30-40% ampicillin-resistant** → use ceftriaxone empirically
- **Rifampin prophylaxis** for close contacts (household with unvaccinated child <4 years)
- **Chocolate agar** required for culture

## Sources

- [CDC: Hib Guidelines 2024]
- [AAP: Hib Vaccination 2023]

## Media

N/A
